Literature DB >> 19050972

Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis.

Ju-Li Koh1, Tristan D Yan, Derek Glenn, David L Morris.   

Abstract

Peritoneal Cancer Index (PCI) has been recognized as an independent prognostic indicator for long-term outcomes. It also influences the likelihood of complete cytoreduction, another principal determinant of long-term survival. The objective of this study was to evaluate the utility of preoperative CT in estimating PCI during the patient selection process. The efficacy of CT in demonstrating peritoneal disease was evaluated by comparing the radiological and intraoperative lesion size and PCI scores using the Wilcoxon signed-rank test. Tumor distribution was assessed in each abdominopelvic region as tumor present versus absent. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated in each abdominopelvic region. Overall, where CT identifies the presence of disease, it portrayed lesion size accurately in 60%, underestimated in 33%, and overestimated in 7% of cases. Analysis of individual abdominopelvic regions demonstrated a statistically significant difference between radiologically and intraoperatively visualized lesion sizes (P < 0.05) except in the epigastrium, left upper, and left flank regions. The sensitivity of CT in detecting peritoneal implants was influenced by lesion size. Small nodules (<0.5 cm) were visualized on CT with only a sensitivity of 11%, which is in contrast to 94% with nodules exceeding 5 cm. Radiological PCI scores significantly underestimated intraoperative PCI (P < 0.001). This study demonstrated that the sensitivity of CT in detecting peritoneal implants was influenced by lesion size and CT PCI significantly underestimated clinical PCI. The role of CT in refining patient selection and improving prognosis remains to be closely evaluated.

Entities:  

Mesh:

Year:  2008        PMID: 19050972     DOI: 10.1245/s10434-008-0234-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  82 in total

1.  Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ingmar Königsrainer
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Use of computed tomography in the management of colorectal cancer.

Authors:  Cher Heng Tan; Revathy Iyer
Journal:  World J Radiol       Date:  2010-05-28

Review 3.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

4.  Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.

Authors:  P Dubé; L Sideris; C Law; L Mack; E Haase; C Giacomantonio; A Govindarajan; M K Krzyzanowska; P Major; Y McConnell; W Temple; R Younan; J A McCart
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 5.  Peritoneal Metastases from Gastrointestinal Cancer.

Authors:  Paul H Sugarbaker
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

6.  Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases.

Authors:  P Sammartino; S Sibio; D Biacchi; M Cardi; P Mingazzini; M S Rosati; T Cornali; B Sollazzo; J Maherfouad Atta; A Di Giorgio
Journal:  Int J Colorectal Dis       Date:  2014-07-01       Impact factor: 2.571

Review 7.  Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A review of the literature.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu; Norihiro Kokudo; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2012-08

Review 8.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

9.  Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review.

Authors:  Paul H Sugarbaker
Journal:  Indian J Surg Oncol       Date:  2019-01-03

Review 10.  Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.

Authors:  Russell N Low
Journal:  J Gastrointest Oncol       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.